BCRX
Price:
$7.98
Market Cap:
$1.65B
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase II clinical trial for complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitor that is in Phase I clinical trial to treat fibrodysplasia ossificans progressiva; and Galidesivir, a RNA dependent-RNA polymerase inhibitor, w...[Read more]
Industry
Biotechnology
IPO Date
1994-03-04
Stock Exchange
NASDAQ
Ticker
BCRX
According to BioCryst Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current ROE is 19.29%. This represents a change of 198.10% compared to the average of 6.47% of the last 4 quarters.
The mean historical ROE of BioCryst Pharmaceuticals, Inc. over the last ten years is 16.75%. The current 19.29% ROE has changed 15.13% with respect to the historical average. Over the past ten years (40 quarters), BCRX's ROE was at its highest in in the June 2019 quarter at 409.32%. The ROE was at its lowest in in the March 2020 quarter at -1030.67%.
Average
16.75%
Median
14.06%
Minimum
8.42%
Maximum
49.73%
Discovering the peaks and valleys of BioCryst Pharmaceuticals, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 192.74%
Maximum Annual ROE = 49.73%
Minimum Annual Increase = -20.64%
Minimum Annual ROE = 8.42%
Year | ROE | Change |
---|---|---|
2023 | 49.73% | 192.74% |
2022 | 16.99% | 11.45% |
2021 | 15.24% | -20.64% |
2020 | 19.21% | 34.47% |
2019 | 14.28% | 3.25% |
2018 | 13.83% | 32.87% |
2017 | 10.41% | 6.87% |
2016 | 9.74% | 15.70% |
2015 | 8.42% | -12.82% |
2014 | 9.66% | 35.59% |
The current ROE of BioCryst Pharmaceuticals, Inc. (BCRX) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
27.32%
5-year avg
23.09%
10-year avg
16.75%
BioCryst Pharmaceuticals, Inc.’s ROE is greater than TG Therapeutics, Inc. (-38.21%), greater than Axsome Therapeutics, Inc. (-174.48%), greater than Intercept Pharmaceuticals, Inc. (-78.24%), less than Seres Therapeutics, Inc. (313.56%), greater than Madrigal Pharmaceuticals, Inc. (-95.61%), greater than Kezar Life Sciences, Inc. (-54.50%), greater than Immunic, Inc. (-169.82%), less than Atara Biotherapeutics, Inc. (2.02%), greater than Pieris Pharmaceuticals, Inc. (-97.28%), greater than Apellis Pharmaceuticals, Inc. (-139.02%), greater than Blueprint Medicines Corporation (-85.25%), greater than Karuna Therapeutics, Inc. (-30.79%), greater than Mirati Therapeutics, Inc. (-81.10%), greater than Day One Biopharmaceuticals, Inc. (-122.70%), greater than Anavex Life Sciences Corp. (-30.62%), greater than Cassava Sciences, Inc. (-10.98%), greater than INmune Bio, Inc. (-101.34%), greater than BioVie Inc. (-294.42%), greater than Cognition Therapeutics, Inc. (-118.11%), greater than Viking Therapeutics, Inc. (-15.05%), less than X4 Pharmaceuticals, Inc. (32.93%), greater than PDS Biotechnology Corporation (-137.06%),
Company | ROE | Market cap |
---|---|---|
-38.21% | $3.41B | |
-174.48% | $4.47B | |
-78.24% | $794.69M | |
313.56% | $145.36M | |
-95.61% | $5.30B | |
-54.50% | $40.82M | |
-169.82% | $120.71M | |
2.02% | $46.55M | |
-97.28% | $22.50M | |
-139.02% | $5.00B | |
-85.25% | $5.47B | |
-30.79% | $12.60B | |
-81.10% | $4.12B | |
-122.70% | $1.25B | |
-30.62% | $436.70M | |
-10.98% | $1.29B | |
-101.34% | $116.32M | |
-294.42% | $15.23M | |
-118.11% | $22.87M | |
-15.05% | $6.00B | |
32.93% | $109.78M | |
-137.06% | $107.88M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like BioCryst Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like BioCryst Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is BioCryst Pharmaceuticals, Inc.'s ROE?
How is the ROE calculated for BioCryst Pharmaceuticals, Inc. (BCRX)?
What is the highest ROE for BioCryst Pharmaceuticals, Inc. (BCRX)?
What is the 3-year average ROE for BioCryst Pharmaceuticals, Inc. (BCRX)?
What is the 5-year average ROE for BioCryst Pharmaceuticals, Inc. (BCRX)?
How does the current ROE for BioCryst Pharmaceuticals, Inc. (BCRX) compare to its historical average?